Last Updated : April 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Inlyta (RFA) | Axitinib | Metastatic Renal Cell Carcinoma | N/A | Complete | ||
| Talzenna | talazoparib | Metastatic castration-resistant prostate cancer (mCRPC) | Suspended | |||
| Nurtec ODT | rimegepant | Migraine, prevention | Withdrawn | |||
| Eylea HD | aflibercept 8mg/0.07mL | macular degeneration, age related | Active | |||
| Eylea HD | aflibercept 8mg/0.07mL | diabetic macular edema | Active | |||
| Tecvayli | teclistamab | Relapsed or refractory multiple myeloma | Active | |||
| Paxlovid | nirmatrelvir/ritonavir | Mild-to-moderate COVID-19, treatment | Active | |||
| Isturisa | osilodrostat | Endogenous Cushing’s syndrome | Suspended | |||
| Remsima | infliximab | Crohn’s disease | Active | |||
| Hemgenix | etranacogene dezaparvovec | Hemophilia B | Active |
Last Updated : April 19, 2024